Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
COO
$81.04+Infinity%1D
Analyst Views on COO
Wall Street analysts forecast COO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for COO is 81.20 USD with a low forecast of 64.00 USD and a high forecast of 96.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast COO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for COO is 81.20 USD with a low forecast of 64.00 USD and a high forecast of 96.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
5 Hold
1 Sell
Moderate Buy
Current: 81.530
Low
64.00
Averages
81.20
High
96.00
Current: 81.530
Low
64.00
Averages
81.20
High
96.00
Goldman Sachs
Sell
maintain
$64 -> $71
2025-12-08
Reason
Goldman Sachs
Price Target
$64 -> $71
2025-12-08
maintain
Sell
Reason
Goldman Sachs raised the firm's price target on Cooper Companies to $71 from $64 and keeps a Sell rating on the shares. Cooper reported a relatively in line Q4, and adjusted EPS guidance was well ahead of consensus estimates, the analyst tells investors in a research note. While Cooper is making progress on improving the financial profile of the business, the overall trajectory of the top-line is relatively unchanged vs. the firm's prior estimates.
Citi
Neutral
maintain
$72 -> $88
2025-12-08
Reason
Citi
Price Target
$72 -> $88
2025-12-08
maintain
Neutral
Reason
Citi raised the firm's price target on Cooper Companies to $88 from $72 and keeps a Neutral rating on the shares. The company reported better than expected fiscal Q4 results after repeated misses, the analyst tells investors in a research note.
Barclays
Matt Miksic
Overweight
maintain
$85 -> $91
2025-12-08
Reason
Barclays
Matt Miksic
Price Target
$85 -> $91
2025-12-08
maintain
Overweight
Reason
Barclays analyst Matt Miksic raised the firm's price target on Cooper Companies to $91 from $85 and keeps an Overweight rating on the shares. The company reported "solid" fiscal Q4 results with stabilizing growth trends in both Vision and Surgical, the analyst tells investors in a research note.
Baird
Outperform
maintain
$85 -> $98
2025-12-05
Reason
Baird
Price Target
$85 -> $98
2025-12-05
maintain
Outperform
Reason
Baird raised the firm's price target on Cooper Companies to $98 from $85 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results which suggested a step in the right direction.
About COO
The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
